<DOC>
	<DOCNO>NCT00269919</DOCNO>
	<brief_summary>The purpose study evaluate long-term efficacy safety long-acting injectable formulation risperidone ( antipsychotic medication ) influence quality life , participant schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusion hallucination , withdrawal self ) .</brief_summary>
	<brief_title>An Efficacy Safety Study Long-Term Risperidone Microspheres Participants With Schizophrenia</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) single-arm , prospective study ( study follow participant forward time ) risperidone microspheres participant schizophrenia . Participants treat intramuscular ( muscle ) injection either 25 milligram ( mg ) 37.5 mg 50 mg risperidone twice weekly , every 2 week 2 year . The total duration study 2 year . The efficacy participant primarily evaluate total Positive Negative Syndrome Scale ( PANSS ) score . Participants ' quality life safety monitor throughout study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Participants diagnose schizophrenia schizoaffective disorder ( inpatient outpatient ) Participants currently symptoms well control stable dose oral antipsychotic medication Participants sign informed consent form Participants never receive previous antipsychotic treatment Participants receive clozapine last 3 month Participants serious unstable medical condition , include laboratory abnormality Participants history , current symptom tardive dyskinesia ( complication neuroleptic therapy involve involuntary movement facial muscle ) neuroleptic malignant syndrome ( rare psychotropicdrug reaction , may characterize confusion , reduce consciousness , high fever pronounce muscle stiffness ) Female participant pregnant breastfeeding , childbearing age without adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Risperidal Consta</keyword>
</DOC>